BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+6.86%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$4.54B
AUM Growth
+$4.54B
(+1.7%)
Cap. Flow
-$108M
Cap. Flow
% of AUM
-2.39%
Top 10 Holdings %
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13
Top Buys
| 1 |
Akero Therapeutics
AKRO
|
$39.2M |
| 2 |
Immunocore
IMCR
|
$38.3M |
| 3 |
BPMC
Blueprint Medicines
BPMC
|
$36.5M |
| 4 |
Thermo Fisher Scientific
TMO
|
$20M |
| 5 |
Edgewise Therapeutics
EWTX
|
$17.7M |
Top Sells
| 1 |
Incyte
INCY
|
$35.5M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$29.9M |
| 3 |
Intuitive Surgical
ISRG
|
$25.6M |
| 4 |
Boston Scientific
BSX
|
$20M |
| 5 |
Cencora
COR
|
$19M |
Sector Composition
| 1 | Healthcare | 99.88% |
| 2 | Technology | 0.01% |
| 3 | Consumer Discretionary | 0.01% |
| 4 | Communication Services | 0.01% |
| 5 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
NeoGenomics
NEO
$1.14B
| $6.67M | 0.15% |
913,082
-303,674
| -25% | -$2.22M |
|
|
WAY
77
Waystar Holding Corp
WAY
$6.6B
| $6.16M | 0.14% |
150,610
+6,184
| +4% | +$253K |
|
78
Axsome Therapeutics
AXSM
$6.05B
| $5.87M | 0.13% |
56,253
-40,154
| -42% | -$4.19M |
|
79
Glaukos
GKOS
$5.5B
| $5.78M | 0.13% |
55,926
| – | – |
|
80
Gilead Sciences
GILD
$140B
| $5.7M | 0.13% |
51,416
-3,606
| -7% | -$400K |
|
81
IQVIA
IQV
$32.4B
| $5.31M | 0.12% |
33,700
-27,368
| -45% | -$4.31M |
|
82
Ascendis Pharma
ASND
$11.8B
| $4.95M | 0.11% |
28,655
+26,755
| +1,408% | +$4.62M |
|
83
Baxter International
BAX
$12.7B
| $4.61M | 0.1% |
152,291
-304,155
| -67% | -$9.21M |
|
|
OMDA
84
Omada Health, Inc. Common Stock
OMDA
$1.36B
| $4.58M | 0.1% |
+250,000
| New | +$4.58M |
|
85
BrightSpring Health Services
BTSG
$4.2B
| $4.52M | 0.1% |
191,706
-50,043
| -21% | -$1.18M |
|
86
10x Genomics
TXG
$1.74B
| $3.78M | 0.08% |
326,751
+95,754
| +41% | +$1.11M |
|
87
BioNTech
BNTX
$24.2B
| $3.73M | 0.08% |
35,039
+27,075
| +340% | +$2.88M |
|
88
Cardinal Health
CAH
$35.5B
| $3.36M | 0.07% |
20,012
-764
| -4% | -$128K |
|
89
Legend Biotech
LEGN
$6.41B
| $3.03M | 0.07% |
85,438
-5,753
| -6% | -$204K |
|
90
AstraZeneca
AZN
$249B
| $2.68M | 0.06% |
38,400
-1,600
| -4% | -$112K |
|
91
Illumina
ILMN
$15.8B
| $2.64M | 0.06% |
27,624
| – | – |
|
|
92
Cencora
COR
$56.5B
| $2.39M | 0.05% |
7,970
-63,390
| -89% | -$19M |
|
93
Merck
MRK
$214B
| $2.24M | 0.05% |
28,239
-203,132
| -88% | -$16.1M |
|
|
KMTS
94
Kestra Medical Technologies, Ltd. Common Stock
KMTS
$829M
| $2.22M | 0.05% |
133,761
| – | – |
|
95
CVS Health
CVS
$94B
| $2.08M | 0.05% |
30,096
-1,659
| -5% | -$114K |
|
96
SPDR S&P 500 ETF Trust
SPY
$653B
| $1.92M | 0.04% |
3,100
-2,560
| -45% | -$1.58M |
|
97
Bristol-Myers Squibb
BMY
$96.5B
| $1.72M | 0.04% |
37,177
+11,611
| +45% | +$537K |
|
98
Pfizer
PFE
$142B
| $1.72M | 0.04% |
70,915
-49,831
| -41% | -$1.21M |
|
|
VRNA
99
Verona Pharma
VRNA
$9.16B
| $1.51M | 0.03% |
15,927
-45,334
| -74% | -$4.29M |
|
100
Doximity
DOCS
$12.7B
| $1.46M | 0.03% |
23,816
| – | – |
|